semaglutide saxenda Novo Nordisk readies new obesity treatment after < Pharma < Article Wegovy vs. Saxenda: Comparing Two

By the 1970s, one hormone was identified as an incretin candidate: Gastric Inhibitory Polypeptide (GIP) , discovered in 196970, which was found to stimulate insulin secretion (and renamed Glucose-Dependent Insulinotropic Polypeptide ) ( [30] )

The safety of using GHSs over the short and long term is According to a 2017 review, common side effects of using GHS may include: increased appetite elevated blood sugar levels fluid retention GHSs may also decrease the bodys sensitivity to the hormone insulin, making it more difficult to regulate blood sugar levels

Castilho-Fernandes, A

Updated April 2026

IV infusion therapy involves the controlled intravenous administration of fluids, electrolytes, vitamins, antioxidants, and metabolic support formulations under medical supervision